Multiple myeloma (MM), a progressive hematological neoplasm, is thought to result from multiple genetic events affecting the terminal plasma cell. However, genetic aberrations related to MM are seldom reported. Using our in-house array-based comparative genomic hybridization system to locate candidate target genes with following their expression analysis, we identified POU2AF1 at 11q23.1 as a probable amplification target in MM cell lines. POU2AF1 is a B-cell-specific transcriptional coactivator, which interacts with octamer-binding transcription factors Oct-1 and Oct-2, and augments their function. Downregulation of POU2AF1 expression by specific smallinterfering RNA (siRNA) inhibited MM cell growth, whereas ectopic expression of POU2AF1 promoted growth of MM cells. Among putative transcriptional targets for POU2AF1, B-cell maturation factor, TNFRSF17, enhanced its transcription by POU2AF1, and POU2AF1 directly bound to an octamer site within the 5 0 region of TNFRSF17. Expression level of TNFRSF17 was closely correlated with that of POU2AF1 in cell lines and primary samples of MM, and decreasing TNFRSF17 expression by means of TNFRSF17 siRNA inhibited MM cell growth. Taken together, our results suggest that POU2AF1, when activated by amplification or other mechanisms, may contribute to progression of MM by accelerating growth of MM cells through direct transactivation of one of its target genes, TNFRSF17.
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Introduction
Multiple myeloma (MM) is a malignancy characterized by clonal expansion of plasma cells, although clinical features, responses to treatment and survival times vary widely among MM patients. Despite advances in systemic and supportive therapies, MM remains an incurable disease. Cytogenetic and molecular studies have provided evidence of marked heterogeneity of chromosomal aberrations in MM cells (Seidl et al., 2003) . In particular, translocations involving the immunoglobulin heavy chain (IGH) locus at 14q32 and different chromosomal partners occur in approximately 60% of MM cases (Fonseca et al., 2004) . The most often recurrent IGH translocations in MM patients include t(11;14)(q13;q32), t(4;14)(p16.3;q32), t(6;14)(p21;q32), t(14;16)(q32;q23) and t(14;20)(q32;q11), which, respectively, deregulate the CCND1, FGFR3 and MMSET/ WHSC1, CCND3, MAF and MAFB genes. However, these translocations are not sufficient for malignant progression of MM; therefore, an accumulation of additional genetic alterations affecting tumor-related elements, such as proto-oncogenes and tumor-suppressor genes, appears to be necessary for the emergence of a fully malignant phenotype. Unraveling the nature and sequence of these events may have a critical impact on identification of the molecular mechanisms leading to distinct disease entities, potentially to allow definition of prognostic risk groups and development of targeted therapies of this disease.
Changes in genomic copy numbers can influence expression or activity of MM-associated genes. Comparative genomic hybridization (CGH) experiments using arrayed genomic DNAs (array-CGH), such as those derived from bacterial artificial chromosome (BAC) and/ or P1-artificial chromosome (PAC) libraries, is currently one of the most powerful tools for detecting and simultaneously localizing losses or gains of genetic material throughout the genome (Inazawa et al., 2004) . Combined with the human genome database, array-CGH enables high-throughput quantitative measurement of DNA copy numbers at high resolution, allowing rapid discovery of novel tumor-suppressor genes and proto-oncogenes.
In the course of a program to screen a panel of MM cell lines for copy-number aberrations in a genome-wide manner using an in-house BAC/PAC array, we identified amplification at 11q23. Frequent copy-number aberrations at 11q23 and/or 11q25 in primary MM have been reported previously (Cremer et al., 2005a, b) , but the presumptive target genes have never been identified; this prompted us to perform a detailed search for specific amplification target(s) involved in the pathogenesis of MM. Within the 3-Mb smallest region of overlap (SRO) at 11q23, we successfully identified POU2AF1, also known as OBF-1/OCA-B/BOB.1, which is a B-cell-specific transcriptional co-activator that interacts with the octamer-binding transcription factors Oct-1 and Oct-2, and augments their function (Luo et al., 1992; Luo and Roeder, 1995) .
Here we provide evidence to show that POU2AF1 is a likely target for amplification in MM, although its amplification/overexpression was a relatively infrequent event in this disease. Increases and decreases in POU2AF1 expression respectively promoted and inhibited growth of MM cells in our experiments. Moreover, expression of TNFRSF17, also known as B-cell maturation antigen, was directly transactivated by POU2AF1, and downregulation of TNFRSF17 inhibited growth of MM cells that overexpressed POU2AF1. The expression levels of POU2AF1 and TNFRSF17 were tightly correlated in MM cell lines as well as in primary specimens. These results suggested that overexpressed POU2AF1 through amplification or other mechanisms promotes growth of MM cells, at least in part, by way of its effect on the amount of TNFRSF17 in the plasma cell, thereby functioning as an oncogene during myelomagenesis by activating this transcriptional target.
Results

Array-CGH analysis of MM cell lines
We assessed copy-number aberrations in each of the 28 MM cell lines by array-CGH analysis using our in-house BAC/PAC-based array, MCG Cancer Array-800 (Inazawa et al., 2004) . Figure 1a shows the frequencies of copy-number gains and losses across the entire genomes of all 28 lines. Gains of DNA that occurred in more than 50% of clones were most often at 1q, 7q and 8q; the most frequent losses were mainly at 1p, 13q, 14q, 17p and 22q. Representative genes in these clones are MYC (8q, 55%), RB1 (13q, 81%) and TP53 (17p, 51%), all of which are often aberrant in MM cell lines and primary MM cells. The most frequent losses we observed were in the 14q32 region, where the immunoglobulin heavy constant gamma 1 gene (IGHG1) is located (88.9%, Figure 1a ; Supplementary Table S1 ). Translocation in MM is mainly mediated by errors in two different generearrangement mechanisms; it can result in the excision of DNA in the interval between a particular V gene and the corresponding C gene (Kabat, 1972) . The prevalence of IgH translocations is about 85% in primary plasma cell leukemias and more than 90% in MM cell lines (Fonseca et al., 2002; Kuehl and Bergsagel, 2002) . Therefore, we speculated that the deletions of IGHG1 we observed were probably due to translocations, because of the similarity in frequencies.
We chose to focus our attention on remarkable patterns of chromosomal abnormalities such as highlevel amplifications (log 2 ratio >2.0) and homozygous deletions (log 2 ratio oÀ2.0), which are likely to be landmarks of oncogenes and tumor-suppressor genes, respectively (Supplementary Table S1 ). Homozygous deletions had occurred in 11 of the 28 cell lines; MTAP and CDKN2A/p16 at 9p21.3 were both homozygously deleted in cell line KMS-5. Two regions of homozygous deletion on 11q22 and 11q24 were also detected, and representative genes in those regions were YAP1 and FLI1, respectively. The former deletion occurred in four MM cell lines (KMS-20, KMS-28BM, KMS-28PE and MOLP-6), whereas the other occurred only in one, KMS-28PE. Both deletions have also been reported recently in cell lines and primary tumor of MM by array-CGH using oligonucleotide array platform (Carrasco et al., 2006) , although some of the cell lines overlapped with those in our panel. High-level amplifications were detected in 5 of the 28 MM lines, and 16 genes (clones) were represented (Supplementary Table S1 ). High-level amplifications at 11q23, in clones containing POU2AF1 and PPP2R1B, were detected in two cell lines (AMO1 and MOLP-2, Figure 1b ; Supplementary Table S1 ). Since amplification is one of the mechanisms that activate pathogenetically and clinically relevant genes, and overexpressed/activated genes can be good targets for developing novel therapeutic approaches, we chose to analyse the 11q23 amplification further.
Definition of the 11q23 amplicon in MM cell lines by fluorescence in situ hybridization To generate a defined map of the 11q23 amplicon, we performed fluorescence in situ hybridization (FISH) analyses in two of our MM cell lines (AMO1 and MOLP-2) that had exhibited remarkable copy-number gains in this region, using 15 BACs spanning the amplified region and BAC RP11-100N3 locating at 11q11 as a control (Figures 2a and b) . In AMO1 cells, four BACs (RP11-25I9, 262A12, 686G14 and 792P2) produced the highest number of signals as homogenously staining regions (HSRs) on marker chromosomes, whereas three BACs (RP11-262A12, 686G14 and 792P2) showed HSR patterns in MOLP-2 cells (Figures  2a and b; Supplementary Figure S1 ). Therefore, the SRO could be defined between BAC RP11-25I9 and 708L7 as the critical region. According to information gained from human genome databases (http:// www.ncbi.nlm.nih.gov/ and http://genome.ucsc.edu/), the maximal size of this region of interest is approximately 3 Mb.
Expression of candidate target genes within the 11q23 amplicon in MM cell lines Genes activated by copy-number increases and those involved in the progression of tumors are likely to be located in the SROs of amplicons. To determine whether genes amplified at 11q23 were overexpressed in association with amplification, we assessed the expression status of each transcript located within 3-Mb SRO in MM cell lines as described previously . On the basis of our amplicon map, nine known genes were selected from the genome databases ( Figure 2b and Table 1 ). The expression level of each transcript determined by reverse transcription-PCR (RT-PCR), normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH), in AMO1 and MOLP-2 cell lines was divided by the average expression level of each transcript found in two MM cell lines that had exhibited normal copy numbers at 11q23 (KMM1 and KM-5, data not shown), and recorded as a 'fold increase' (Table 1) . Fold increases larger than 2.0 were considered showed broad amplification at 11q, whereas we detected a specifically increased copy numbers of POU2AF1 at 11q23 as a clear green signal (log2 ratio ¼ 2.8) on the MCG Cancer Array-800. Arrows indicate the spot containing the POU2AF1 gene. significant. Among the nine known genes we tested, only POU2AF1 matched that criterion in both AMO1 and MOLP-2 cell lines. Expression level of POU2AF1 mRNA was not correlated with those with its interacting functional partners, Oct-1 and Oct-2 transcription factors (Supplementary Figure S2) . Expression levels of POU2AF1 protein were consistent with their changes in copy number as well (Figure 2c ).
Copy-number gain of POU2AF1 in primary MM samples DNA copy number of POU2AF1 in primary cases of MM was determined by a real-time quantitative PCR using genomic DNA obtained from 23 patients (Figure 2d ). As the normal control of diploid copy number, we first determined the copy-number ratio of POU2AF1 normalized with GAPDH in DNA derived from five independent healthy volunteers. We used Table 1 ). Representative images of mRNA expression levels of known genes except BTG4 (see Table 1 ), detected by RT-PCR in MM cell lines with (AMO1 and MOLP-2) and without (KMM1 and KM-5) 11q23 amplification, are shown. (c) Western-blot analysis of POU2AF1 protein in eight MM cell lines, using anti-POU2AF1 antibody. Anti-b-actin antibody was used for reprobing to show equivalent loading and transfer of proteins. The copy number of POU2AF1 is given under the lane for each cell line. AMO1 and MOLP-2 cells, with amplified POU2AF1, showed overexpression of POU2AF1 at the levels of both mRNA and protein. (d) Copy-number ratios of POU2AF1 in 23 primary cases of MM determined by real-time quantitative PCR. The abundance of the POU2AF1 gene in genomic DNA of each sample was normalized by the corresponding endogenous control GAPDH value, and recorded as copy-number ratio. DNAs from five independent healthy volunteers were used as normal controls, and relative copy-number ratio of normal control DNA after normalization was 1.070.28 (the mean7s.d.). We used AMO1 and KMS-21BM cell line having amplification of POU2AF1 as positive controls. Dotted line, the mean þ 2 s.d. (1.56) indicating cutoff ratio for amplification.
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C Zhao et al AMO1 and KMS-21BM cell line having amplification of POU2AF1 as positive controls. To separate cases with or without copy-number gain, the mean þ 2 s.d. of copynumber ratio of POU2AF1 in normal controls was used as the cutoff ratio . The copy-number gain of POU2AF1 was detected in 3 of 23 cases (13.0%), indicating that the POU2AF1 amplification is not the artifact acquired during the establishment of cell lines, although a small number of cases were available for this analysis and the POU2AF1 amplification was infrequently detected. However, this frequency of the POU2AF1 amplification in MM is not so low compared with other gene amplification events: for example, MYCN amplification, one of the most critical genetic events determining prognosis in neuroblastoma, is known to be observed in less than 20% in this disease (Moreau et al., 2006) .
Influence of POU2AF1 expression on proliferation of MM cells
Earlier studies showed that proliferation of POU2AF1
cells is diminished in response to surface IgM crosslinking, and those cells are unable to form germinal centers (Kim et al., 1996; Schubart et al., 1996) . To investigate whether POU2AF1 can also influence proliferation of MM cells, we examined the effect of a decrease or increase in POU2AF1 expression in cell-growth assays. First, we introduced a POU2AF1-specific small-interfering RNA (siRNA) into AMO1 and KMS-21BM cells, which express POU2AF1 highly and moderately, respectively, and KMS-12PE and KMS-5 cells, which lack POU2AF1 amplification/overexpression (Figures 2b and c, and Table 1 ). Based on our experiments evaluating transfection efficiency using various concentrations of siRNA in MM cells, we used 200 nM of siRNA to obtain efficient transfection and knockdown effect (Supplementary Figure S3) . Expression of POU2AF1 protein was knocked down 48 h after treatment with two different POU2AF1-siRNAs, compared with a nonspecific control siRNA, in MM cell lines (Figure 3a) .
Downregulation of POU2AF1 expression in AMO1
and KMS-21BM cells by siRNA decreased their growth ( Figure 3b ). POU2AF1-B-siRNA, which was more effective than the 'A' version in knocking down expression of POU2AF1 in AMO1 cells, also showed higher cell growth-inhibiting activity in that cell line. On the other hand, transfection of POU2AF1-siRNA showed almost no effect on growth of KMS-12PE and KMS-5 cells compared with a nonspecific control siRNA, suggesting that the growth inhibitory effect of POU2AF1-siRNAs observed in MM cells with amplification/overexpression of POU2AF1 was caused by neither off-target effect nor simple nonspecific toxicity of siRNA used in this study. Next, we established a cell line stably expressing exogenous POU2AF1 using KMS-11, which had shown low POU2AF1 expression. Between the two isoforms of POU2AF1, we chose p34 for transfection experiments because (a) the p34 isoform exhibited higher transactivating activity as a co-activator on octamer elementcontaining promoters than p35 and (b) p34 is derived from the p35 isoform through post-transcriptional modification (Yu et al., 2001) . We determined expression of the Myc-tagged p34 isoform of POU2AF1 in selected clones by western blotting and by fluorescence immunocytochemistry (FIC), using anti-Myc epitope antibody (Figure 3c ). Exogenously expressed POU2AF1 was observed mainly in nuclei, consistent with previous data (Yu et al., 2001) . Cells stably expressing exogenous POU2AF1 showed increased growth compared with empty vector-(mock-) transfected cells (Figure 3d ).
Regulation of TNFRSF17 expression by POU2AF1
An earlier report showed that expression of some non-Ig genes and/or proteins was affected in POU2AF1-deficient mice (Teitell, 2003) . The candidate transcriptional targets for POU2AF1 included genes encoding BAFFR, TNFRSF17, Bcl-2, cyclin D3 and osteopontin (Samardzic et al., 2002; Brunner et al., 2003; Kim et al., 2003; Lins et al., 2003) , proteins that might be Known genes were selected from the SRO of 11q23 amplicon in MM cell lines (Figure 2b) . The expression level of each gene in each cell line was divided by the average value of that in KMM1 and KM-5 cell lines (reference value), which have normal copy numbers of 11q, after normalization with GAPDH, and recorded as a fold increase in relative expression level. Fold increases in relative expression levels >2.0 were considered significant and are shown in bold type. The single gene that was significantly overexpressed as a consequence of amplification at 11q23 is highlighted with gray background. c NT indicates that expression level is below the lower limit of quantification.
Amplification of POU2AF1 in multiple myeloma C Zhao et al considered to participate in aspects of neoplastic development or progression such as proliferation, survival, cell cycling, adhesion or migration (Ladanyi et al., 1992; Claudio et al., 2002; Hideshima et al., 2004; Novak et al., 2004; Standal et al., 2004; Heckman et al., 2006) . To investigate whether, as a transcriptional coactivator, POU2AF1 regulates expression of those genes in MM cells, we examined the mRNA level of each of them in MM cells treated with POU2AF1-siRNA or in a MM cell line stably expressing POU2AF1, by real-time quantitative RT-PCR. Among the five candidates, only TNFRSF17 mRNA was decreased in AMO1 and KMS-21BM cells treated with POU2AF1 siRNA compared with control cells treated with nonspecific siRNA (Figure 4a and data not shown), and elevated in cells stably expressing POU2AF1 compared with cells transfected with wild vector alone (mock, Figure 4a ). Relatively small increase and decrease in TNFRSF17 mRNA expression through POU2AF1 overexpression and knockdown in MM cells (Figure 4a ) suggest that TNFRSF17 transcription may also be regulated or modified by other regulatory transcription factors or cofactors in this cell lineage. Using a transcription element search software package, RecGroupScan (http://www.mgs.bionet.nsc.ru/ mgs/programs/yura/RecGropScanStart.html), we found Amplification of POU2AF1 in multiple myeloma C Zhao et al an octameric motif upstream of the transcription start site of TNFRSF17 (Figure 4b ). To determine whether POU2AF1 directly regulates the transcription of this gene in MM cells, we performed chromatin immunoprecipitation (ChIP) assays to examine whether a transcriptional complex containing POU2AF1 could occupy this motif in vivo, by using AMO1 cells and KMS-11 cells stably expressing POU2AF1. In both cell populations, the POU2AF1 complex bound to the region containing the specific octamer upstream of 0 untranslated and coding regions of exon 1, respectively. Arrows denote primers used for ChIP assay. (Left lower) Binding of POU2AF1 to the endogenous TNFRSF17 cis-regulatory region in multiple myeloma (MM) cells. Chromatin immunoprecipitations from AMO1 cells and from transfected KMS-11 cells stably expressing POU2AF1 were performed as described in Materilas and methods. PCR products were resolved on 3% agarose by electrophoresis. DNA from lysates before immunoprecipitation was used as positive input control. The primer set amplified the region containing an octamer site (arrows). The experiment was repeated twice. (Right) Reporter assays of wild type and a point mutant of the octamer. Equal amounts of reporters containing either wild or mutant octamer-site sequences were introduced into cells with Renilla luciferase vector, along with expression vectors for POU2AF1 isoforms p34 or p35, or empty vector (mock) alone. Firefly luciferase activities in samples were normalized to Renilla luciferase activities in the same specimens, and relative luciferase activity was calculated based on considering the value in cells with wild-type octamer and mock expression vector as 1. The data presented are the mean7s.d. of three separate experiments, each performed in triplicate. (c) Correlation between expression levels of POU2AF1 and TNFRSF17 mRNAs in MM cell lines. The mRNA level of each gene was measured by quantitative RT-PCR, as described in Materials and methods. Expression levels were normalized to that of b2-microglobulin (b2M). (d) Correlation between expression of POU2AF1 and TNFRSF17 mRNAs in 32 primary MM specimens as well as in normal plasma cells from two individuals. Expression levels were normalized to that of b2M.
Amplification of POU2AF1 in multiple myeloma C Zhao et al TNFRSF17 (Figure 4b ). We then tested the transactivating activity of POU2AF1 on a 307-bp fragment encompassing that specific octameric sequence, in KMS-11 cells. As shown in Figure 4b , p35 and p34 isoforms of POU2AF1 showed clear enhancement of the TNFRSF17-wt octameric site; this effect was significantly inhibited by changing the octamer's sequence from wild-type (TTTAGCAT) to mutant (TTCCGCAT).
Correlation of POU2AF1 and TNFRSF17 expression in MM cell lines and primary MM cells To examine the relevance of TNFRSF17 regulation by POU2AF1 in vivo, we determined mRNA levels of POU2AF1 and TNFRSF17 by quantitative real-time RT-PCR in 22 MM cell lines and in MM cells purified from bone marrow aspirates of 32 patients with MM. Significant correlation between mRNA levels of the two genes was observed in the cell lines (correlation coefficient: 0.708, P ¼ 0.0002, the Pearson's correlation test; Figure 4c ) and in the primary MM cells (correlation coefficient: 0.693, Po0.0001, the Pearson's correlation test; Figure 4d ). Notably, case Pt75, Pt78 and Pt97, which showed POU2AF1 amplification in genomic PCR (Figure 2d ), also showed relatively higher mRNA expression of this gene and TNFRSF17. mRNA expression levels of POU2AF1 and TNFRSF17 in normal plasma cells isolated from two individuals were lower than those in primary MM cells (0.023 and 0.003 versus 3.10779.580 in POU2AF1, and o0.001 and o0.001 versus 4.62075.989 in TNFRSF17; mean7s.d.), even though only two normal cases were available for analysis. These observations provided evidence that (a) POU2AF1 is overexpressed through either its amplification or other mechanisms in MM cells and (b) TNFRSF17 resides selectively in a transcriptional pathway with POU2AF1 within terminally differentiated B cells, even within a neoplastic lineage.
Promotion of MM cell growth by TNFRSF17, downstream of POU2AF1
To test whether TNFRSF17 affects cell growth as transcriptional target for POU2AF1, we treated MM cells overexpressing POU2AF1 with a TNFRSF17-specific siRNA. Since no anti-TNFRSF17 antibody suitable for western blotting was available, we first determined levels of mRNA expression between POU2AF1 and TNFRSF17 by quantitative real-time RT-PCR analysis, 48 h after transfection with their respective siRNAs. When we treated the cells with POU2AF1 siRNA, expression of both mRNAs was decreased, but only TNFRSF17 mRNA expression was inhibited by TNFRSF17 siRNA (Figures 5a and b) . This result confirmed TNFRSF17 as a downstream target of POU2AF1. After treatment with TNFRSF17 siRNA, as with POU2AF1 siRNA, growth of AMO1 and KMS21BM cells was significantly inhibited compared to growth of the same cells treated with a nonspecific (control) siRNA (Figure 5c ). Combined with the results described above, these data suggest that overexpressed POU2AF1 accelerates growth of MM cells by activating expression of TNFRSF17.
Discussion
Abnormalities of chromosome 11, especially 11q, which can involve translocations and/or gains or losses of DNA, are common events in MM (Tricot et al., 1995) . Gains of 11q in plasma cells have been reported in 20-45% of MM patients, ranging from trisomies to single chromosomal bands (Cigudosa et al., 1998; Gutierrez et al., 2001) . Aberration of 11q13 is probably due to cyclin D1, which is overexpressed as a result of translocation or an amplification mechanism (Sonoki et al., 1998; Hoechtlen-Vollmar et al., 2000) . The targets in other affected regions of 11q, such as 11q23 and 11q25 (Gonzalez et al., 2004; Carrasco et al., 2006) , remain unknown. Using in-house array-CGH, we detected high-level amplification at 11q23 in two MM cell lines, AMO1 and MOLP-2. After analysing all nine known genes located within the SRO of this amplicon, we found that POU2AF1, a B-cell-specific transcriptional coactivator, was consistently overexpressed in MM cell lines that exhibited increased copy numbers in that region. Functional analyses in combination with one of its possible transcriptional targets, TNFRSF17, suggested that POU2AF1 is a likely target of amplification in MM and, when overexpressed by any mechanism, contributes to the pathogenesis of the disease by transactivating a specific downstream transcriptional target, TNFRSF17.
POU2AF1 functions as an essential and nonredundant co-activator by binding Oct-1 and Oct-2 transcription factors. It is required for transcriptional activity at the octameric DNA element ATGCAAAT and similar regulatory sequences (Cepek et al., 1996; Gstaiger et al., 1996) . Since expression of POU2AF1 is largely restricted to B lymphocytes, the functions of this protein in normal B-cell development have been extensively studied. In mice, although disruption of the POU2AF1 locus resulted in failure to form germinal centers and reduced levels of secondary Ig isotypes, B cells from POU2AF1 À/À mice were similar to normal resting B cells (Nielsen et al., 1996; Schubart et al., 2001 ). Additionally, mice in which the lymphoid compartment was replaced with cells lacking both Oct-2 and POU2AF1, B-cell development and Ig expression were mostly unchanged, although the population of mature peripheral B cells was reduced (Schubart et al., 2001) . These studies suggested that POU2AF1 and Oct factors are not as important for expression of immunoglobulins as much as for determination of cell fate and maintenance of the B-cell population.
Little information is available regarding the role of POU2AF1 in malignant transformation and proliferation in B-cell lineages. Overexpression of POU2AF1 has been observed in germinal center-derived lymphomas (Greiner et al., 2000) . Recently, Largo et al. (2006) reported that POU2AF1 locates within frequently Amplification of POU2AF1 in multiple myeloma C Zhao et al gained region and is overexpressed regardless of copynumber status in MM cells compared with universal human RNA. Heckman et al. (2006) reported that Oct factors and POU2AF1 mediate cell survival in t(14;18) lymphoma cells by directly activating the antiapoptotic gene Bcl-2, and they may therefore play a role in malignant transformation. However, they evaluated only the number of apoptotic cells, not total cell growth or the numbers of proliferative cells, after knockdown of those factors. Since studies with POU2AF1-deficient B cells have indicated that POU2AF1 targets genes are responsible for B-cell proliferation and signaling (Kim et al., 2003) and that expression of the antiapoptotic factor Bcl-2 in POU2AF1 À/À mice is able to rescue early B lymphopoiesis but not B-cell responsiveness (Brunner et al., 2003) , a primary role of POU2AF1 and Oct elements might be to act as cell-growth and/or survival factors in normal and malignant development of B-cell lineages. Our experiments using stable transfectants expressing POU2AF1 and siRNA-induced knockdown of POU2AF1 in cell lines highly expressing the gene successfully demonstrated the growth-promoting effect of overexpressed POU2AF1 in human MM cells. Expression of bcl-2 was not correlated with amplification or expression levels of POU2AF1 in the MM cell lines we examined (data not shown), suggesting that this protein may have different transcriptional targets and might show different effects among various malignancies.
Since POU2AF1 is a specific co-activator at octameric promoters, its growth-promoting effect on MM cells may be due to its ability to activate transcription of certain target gene(s). Despite the fact that a large number of genes specifically expressed in B cells contain octamer motifs in their regulatory regions, only a small number of POU2AF1-dependent genes have been described, among them, BAFFR, TNFRSF17, bcl-2, cyclin D3 and osteopontin (Samardzic et analyses were performed 48 h after transfection. For normalization, values were adjusted to b-actin levels, and % relative expression levels were calculated based on setting the nonspecific control siRNA levels as 100. (c) Decrease in relative number of living cells (cell viability), determined by colorimetric water-soluble tetrazolium salt (WST) assay, after downregulation of TNFRSF17 expression in POU2AF1 siRNA-treated AMO1 and KMS-21BM cells compared to control siRNA treated cells. *Po0.05 with unpaired Student's t-test.
Amplification of POU2AF1 in multiple myeloma C Zhao et al Brunner et al., 2003; Kim et al., 2003; Lins et al., 2003) . We have now confirmed that of this group of genes, only TNFRSF17 serves as a transcriptional target for POU2AF1 in MM cells. Therefore, POU2AF1 may activate genes differently in MM cells than in cells belonging to normal B-cell lineages, or t(14;18) lymphoma cells. Indeed, others have shown that in MM cells, TNFRSF17 is expressed with its ligand BAFF, a B-cell-activating factor, which modulates the proliferative capacity of cytokine-stimulated MM cells through its ability to promote survival (Schneider et al., 1999; Novak et al., 2004) . Although two other BAFF receptors, TACI and BAFF-R, are also expressed in MM cells (Novak et al., 2004) , TNFRSF17 may function as an important receptor of BAFF to transduce signals for cell survival and proliferation, given that TNFRSF17 is a member of the TNFR superfamily lacking a 'death domain' and given the fact that its overexpression in HEK293 cells activates nuclear factorkB, p38 and c-Jun N-terminal kinase (Hatzoglou et al., 2000) . Using gene-specific siRNAs and ChIP assays, we demonstrated that TNFRSF17, when transcriptionally induced by POU2AF1, contributes to growth of MM cells. In our ongoing study (C Zhao and J Inazawa, unpublished data), we also confirmed that a list of genes possibly transactivated by POU2AF1, which was compiled by our preliminary expression-array analysis using POU2AF1-B-siRNA-transfected U266 myeloma cell line, in a comparison with nonspecific siRNAtransfected counterparts, included POU2AF1, but did not include other four genes.
Of the two isoforms of POU2AF1, p34 and p35, p34 is the predominant isoform expressed in MM cells (Figure 2c ). Others have noted that p34 had higher transcription activity than p35 (Yu et al., 2001) , and our experiments using reporter constructs containing the Oct sequence upstream of TNFRSF17 (Figure 4b) confirmed it. Therefore, we introduced isoform p34 into the KMS-11 cell line to establish POU2AF1-stable transfectants that exhibited greater growth than their parent MM cells, suggesting that at least the p34 isoform of POU2AF1 could exhibit oncogenic activity during myelomagenesis. However, since p35 also affected expression of TNFRSF17 (Figure 4b) , even though weakly, it is possible that both isoforms can contribute to growth of MM cells.
Recent reports suggested that augmented expression of POU2AF1 does not occur at the transcriptional level (Husson et al., 2002; Robetorye et al., 2002; Heckman et al., 2006) , and that post-translational modification of POU2AF1 may contribute to its stability and activity in t(14;18) lymphoma cells (Tanaka and Herr, 1990; Zwilling et al., 1997) . However, t(14;18) lymphoma cells treated with specific siRNA have shown decreases in both POU2AF1 mRNA and its protein product (Heckman et al., 2006) . In this study, we demonstrated that (a) both POU2AF1 mRNA and protein were upregulated in MM cells where amplification had occurred at 11q23.1 and (b) the level of POU2AF1 mRNA was correlated with that of one of its transcriptional targets, TNFRSF17. These data suggest that POU2AF1 expression, at least in MM cells, is regulated at least partially at the transcriptional level. The mechanism(s) responsible for augmented POU2AF1 expression in various malignancies, including MM, need to be elucidated.
In summary, the study presented here has demonstrated that POU2AF1 is a target for amplification at 11q23 in MM. POU2AF1 mediates growth of MM cells, at least in part, by activating one of its transcriptional targets, TNFRSF17. As the POU2AF1-TNFRSF17 pathway appears to be important for myelomagenesis, it represents a potentially suitable target for development of novel reagents for treatment of MM, a hematological malignancy that is not curable at present.
Materials and methods
MM cell lines and primary MM specimens
We examined 28 human MM cell lines established from primary samples, (AMO1, KMM1, KM-1, KM-4, KM-5, , KMS-12BM, KMS-12PE, KMS-21BM, KMS-21PE, KMS-28BM, KMS-28PE, HS, ILKM-10, ILKM-12, ILKM-13, MOLP-2, MOLP-6 and OPM-2) and one Epstein-Barr virus-transformed normal lymphocyte cell line. All lines were maintained in RPMI-1640 supplemented with 10% fetal bovine serum. Genomic DNA was available from all cell lines; RNA and chromosomal spreads were available from 22 of them.
Primary MM specimens were obtained from 32 patients who were undergoing treatment in Nagoya City University Hospital. At the time of diagnosis, 1-2 ml of bone marrow aspirate was obtained from each patient after written informed consent according to guidelines approved by the Institutional Ethical Committee. MM cells were purified from the populations of mononuclear cells in marrow aspirates by positive selection, using anti-CD138 antibody-coated beads and an automatic magnetic cell sorting system (Miltenyi Biotec, Auburn, CA, USA) as described elsewhere (Miura et al., 2003) . Normal plasma cells corrected from patients with nonneoplastic diseases were enriched using the same method described as above. RNA was isolated from all specimens, whereas genomic DNA was available from 23 of 32 MM patients.
Array-CGH analysis
In-house MCG Cancer Array-800 contains 800 BAC/PAC clones carrying genes or sequence-tagged-site markers of potential importance in carcinogenesis (http://www. cghtmd.jp/cghdatabase/index.html; Inazawa et al., 2004) . Hybridizations were carried out as described elsewhere (Sonoda et al., 2004) . The hybridized slides were scanned with a GenePix 4000B (Axon Instruments, Foster City, CA, USA). Acquired images were analysed with GenePix Pro 6.0 imaging software (Axon Instruments). Fluorescence ratios were normalized so that the mean of the middle third of log 2 ratios across the array was zero. The thresholds for copy-number gain and loss were set at log 2 ratios of 0.4 and À0.4, respectively (Takada et al., 2005) , and we defined log 2 ratios >2.0 and oÀ2.0 as high-level amplifications and homozygous deletions, respectively.
Fluorescence in situ hybridization
Metaphase chromosomes were prepared from normal male lymphocytes and from each MM cell line. fluorescence in situ Amplification of POU2AF1 in multiple myeloma C Zhao et al hybridization analyses were performed, as described elsewhere , using BACs located around the region of interest as probes. The copy-number and molecular organization of the region of interest were assessed according to the hybridization patterns observed on both metaphase and interphase chromosomes.
Semiquantitative RT-PCR and quantitative real-time genomic and RT-PCR Semiquantitative expression analyses were performed by RT-PCR with all transcripts that emerged within the 11q23 amplicon. Single-stranded cDNA was generated from total RNA. PCR products were electrophoresed in 3% agarose gels, and bands were quantified using LAS-3000 (Fujifilm, Tokyo, Japan) and Multi Gauge software (Fujifilm). Quantitative realtime genomic PCR and RT-PCR experiments were performed using an ABI Prism 7900 sequence-detection system (Applied Biosystems, Foster City, CA, USA) as described previously Takada et al., 2005) . Genomic copy number in each primary sample was normalized by dividing it by the corresponding GAPDH value, which is located at 12p13 and rarely involved in MM , and recorded as copy-number ratios. Each assay was performed in duplicate. All primer sequences for amplifying genes chosen for this study are available on request.
Western blotting Anti-POU2AF1, Myc tag and b-actin antibodies were purchased, respectively, from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Cell Signaling Technology (Beverly, MA, USA) and Sigma (St Louis, MO, USA). Cells were lysed in RIPA buffer (10 mM Tris-HCl, 150 mM NaCl, 1 mM ethylenediamine tetraacetic acid, 1% sodium deoxycholate, 0.1% SDS and 1% Triton X-100, pH 7.4) with a proteaseinhibitor cocktail (Roche, Tokyo, Japan). Protein samples were separated by SDS-polyacrylamide gel electrophoresis and electroblotted onto polyvinylidene difluoride membranes. Proteins were detected after incubation with appropriate primary antibodies and peroxidase-conjugated secondary antibodies, followed by development with an enhanced electrochemiluminescence system (Amersham, Tokyo, Japan).
FIC MM cells were centrifuged using Shandon Cytospin (Thermo, Pittsburgh, PA, USA) onto slide glasses, fixed with 4% formaldehyde, permialized with 0.2% Triton X-100 and incubated with polyclonal anti-Myc antibody (Cell Signaling Technology) overnight. Signals were visualized using Alexa 488 goat-anti rabbit antibody (Molecular Probes, Eugene, OR, USA), and the labeled fluorescence was examined by fluorescence microscopy.
Transfection with siRNA and cell-growth assays POU2AF1-specific siRNA was purchased from Japan Bio Services (Saitama, Japan; POU2AF1-A siRNA: CACCUUA CACCGAGUAUGU, POU2AF1-B siRNA: GGUUCUGU GUCUGCAGU). TNFRSF17-specific siRNA (TNFRSF17 siRNA M-011217-00) and a nonspecific control siRNA (D-001206-11-20) were purchased from Dharmacon (Lafayette, CO, USA). For each experiment, 2 Â 10 6 MM cells in logarithmic growth phase were transfected with either 200 nM POU2AF1, TNFRSF17 or control siRNA using Nucleofector (Amaxa, Koeln, Germany) following the manufacturer's protocol. High transfection efficiency of siRNA experiment using this system had been confirmed by our preliminary study using nonspecific control siRNA labeled with fluorescent dye (siGLO RISC-Free siRNA, Dharmacon) in each cell line (8579 and 7576% in AMO1 and KMS-21BM, respectively; the mean7s.d.; data not shown). Transfection efficiency in each experiment was monitored by fluorescein-labeled pmaxGFP analysis. Knockdown efficiency was determined 48 h after transfection by RT-PCR. For measurements of MM cell growth, 1 Â 10 4 cells were seeded into 96-well plates after transfection and the numbers of viable cells were assessed by a colorimetric water-soluble tetrazolium salt (WST) assay (Cell counting kit-8; Dojindo Laboratories, Kumamoto, Japan). Experiments were repeated two times, and each series was performed in triplicate.
Construction of expression plasmids and establishment of stable transfectants Plasmids expressing a Myc-tagged p34 or p35 isoform of POU2AF1 (pCMV-Tag3-p34-POU2AF1 or pCMV-Tag3-p35-POU2AF1, respectively) were obtained by cloning the full coding sequence of each isoform into the pCMV-Tag3 vector (Stratagene, La Jolla, CA, USA) in-frame, along with the Myc-epitope. For establishment of sub-lines that stably expressed the Myc-tagged p34 isoform of POU2AF1, KMS-11 cells were transfected with pCMV-3-p34-POU2AF1 and pCMV-3B empty vector using Nucleofector (Amaxa). Transfected cells were selected with G418 (50 mg/ml) for 3 weeks, and independent clones were established by limiting dilution. Individual clones were analysed for ectopic POU2AF1 expression by western blotting and FIC.
ChIP
ChIP assays were performed as described previously (Sonoda et al., 2004) . Chromatin was immunoprecipitated with anti-POU2AF1 antibody (Santa Cruz Biotechnology), after which PCR was performed with 1/100 of the immunoprecipitated DNA; 1/100 of the solution before adding antibody was amplified as an internal control for the amount of DNA.
Promoter reporter assay
Since an octamer motif at position 5 and/or 6 is critical for the transactivation activities of POU2AF1 (Cepek et al., 1996; Gstaiger et al., 1996) , we designed a mutant octamer site containing two cytosines at those positions. PCR-amplified upstream regions of TNFRSF17 containing wild-type (TTTAGCAT) or mutant (TTCCGCAT) octamer sites were cloned into pGL3-promoter vector (Promega, Madison, WI, USA), and the resulting constructs were designated pGL3-TNFRSF17-wt octamer or pGL3-TNFRSF17-Mut octamer, respectively. Each construct was introduced into KMS-11 cells along with pCMV-Tag3-POU2AF1 isoform p34 or p35 and phRL-TK internal control vector (Promega), using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Firefly luciferase and Renilla luciferase activities were each measured 48 h after transfection by means of the Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity, normalized with Renilla luciferase activity, was divided by the value found in cells transfected with pGL3-TNFRSF17-wt octamer or control vector pCMV-Tag3 (mock) and the difference was recorded as a fold increase in relative luciferase activity.
Statistical analyses
The unpaired Student's t-test was used to compare the significance of differences in cell growth patterns under different treatments. To assess the significance of the correlation, the Pearson's correlation test was used between mRNA expression levels of POU2AF1 and TNFRSF17 after each was normalized; Po0.05 was considered significant in each case.
